06-01-2024, 11:21 PM
Nice find Aly,
Too bad the study didn't publish the brand name of the PM, or the BMI of the patient. The following are some opinions I have. The patient stated they took 2 capsules of pm daily. The two capsules per day of PM (if the patient was being upfront) seems unlikely to elevate triglycerides 2,559 mg/dl (nl 40-150 mg/dL) the patient had at the time ED visits.
The ED additionally found necrotizing pancreatitis. My question is did the patient use other supplements? or follow unhealthy eating habits?. Curious to know what the patients baseline triglyceride level was. PM is known to pack on the pounds. HRT was started after the hospital stay... with supervision. I've posted about how PM increases triglycerides by 15% on both BN forums. This patient had a family history of unspecified hyperlipidemia in the father. With that in mind (a family history of unspecified hyperlipidemia) it's best to seek out medical advice before starting PM.
Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women
Manonai, Jittima MD1; Chittacharoen, Apichart MD1; Udomsubpayakul, Umaporn MSc2; Theppisai, Hathai MD1; Theppisai, Urusa MD1
Author Information
Menopause 15(3):p 530-535, May 2008. | DOI: 10.1097/gme.0b013e31815c5fd8
Objective:
To evaluate the effect of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women and to evaluate the safety of Pueraria mirifica on endometrium; breast tissue; and hematologic, hepatic, and renal systems.
Design:
This was a randomized, double-blind, placebo-controlled study in a university hospital of healthy postmenopausal women aged 45 to 60 years old. Women were enrolled voluntarily and randomly received 20, 30, or 50 mg Pueraria mirifica in capsules or identical placebo once daily for 24 weeks. Outcome measures were lipid profiles, bone-specific alkaline phosphatase level, endometrial thickness, endometrial histology, breast ultrasonography, complete blood count, liver function test, and renal function test.
Results:
After 24 weeks of treatment, 71 women were evaluated. Of the 71 women, 51 randomly received varying doses of Pueraria mirifica and 20 received placebo. Pueraria mirifica and placebo significantly increased triglyceride levels by 15% from baseline levels (P < 0.05). The Pueraria mirifica group showed a significant decrease in bone-specific alkaline phosphatase levels after 24 weeks of treatment compared with the placebo group; from 0.22 ± 0.18 U/L to 0.13 ± 0.01 U/L in the Pueraria mirifica group and from 0.20 ± 0.10 U/L to 0.20 ± 0.14 U/L in the placebo group. Endometrial thickness did not change after treatment in both groups (P > 0.05). No endometrial proliferation or hyperplasia was reported after 24 weeks of treatment in both groups. There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.
Conclusion:
Pueraria mirifica at a dose of 20, 30, and 50 mg/d for a 24-week period demonstrated an estrogen-like effect on bone turnover rate. Pueraria mirifica did not demonstrate an estrogen-like effect on endometrial thickness and endometrial histology. Mild adverse effects occurred after Pueraria mirifica and placebo treatment.
https://journals.lww.com/menopausejournal/abstract/2008/15030/effects_and_safety_of_pueraria_mirifica_on_lipid.22.aspx
Pueraria mirifica group showed a significant decrease in bone-specific alkaline phosphatase levels after 24 weeks of treatment compared with the placebo group; from 0.22 ± 0.18 U/L to 0.13 ± 0.01 U/L in the Pueraria mirifica group and from 0.20 ± 0.10 U/L to 0.20 ± 0.14 U/L in the placebo group
Given patient’s desire for partial transition, low dose transdermal estradiol 0.05 mg patch and spironolactone 50mg BID started. On above regimen, estradiol was 179 pg/mL and total testosterone suppressed at 72 ng/dL. The patient’s triglycerides remained <150 mg/dL with no further complications.
Too bad the study didn't publish the brand name of the PM, or the BMI of the patient. The following are some opinions I have. The patient stated they took 2 capsules of pm daily. The two capsules per day of PM (if the patient was being upfront) seems unlikely to elevate triglycerides 2,559 mg/dl (nl 40-150 mg/dL) the patient had at the time ED visits.
The ED additionally found necrotizing pancreatitis. My question is did the patient use other supplements? or follow unhealthy eating habits?. Curious to know what the patients baseline triglyceride level was. PM is known to pack on the pounds. HRT was started after the hospital stay... with supervision. I've posted about how PM increases triglycerides by 15% on both BN forums. This patient had a family history of unspecified hyperlipidemia in the father. With that in mind (a family history of unspecified hyperlipidemia) it's best to seek out medical advice before starting PM.
- Normal — Less than 150 milligrams per deciliter (mg/dL), or less than 1.7 millimoles per liter (mmol/L)
- Borderline high — 150 to 199 mg/dL (1.8 to 2.2 mmol/L)
- High — 200 to 499 mg/dL (2.3 to 5.6 mmol/L)
- Very high — 500 mg/dL or above (5.7 mmol/L or above)
Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women
Manonai, Jittima MD1; Chittacharoen, Apichart MD1; Udomsubpayakul, Umaporn MSc2; Theppisai, Hathai MD1; Theppisai, Urusa MD1
Author Information
Menopause 15(3):p 530-535, May 2008. | DOI: 10.1097/gme.0b013e31815c5fd8
Objective:
To evaluate the effect of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women and to evaluate the safety of Pueraria mirifica on endometrium; breast tissue; and hematologic, hepatic, and renal systems.
Design:
This was a randomized, double-blind, placebo-controlled study in a university hospital of healthy postmenopausal women aged 45 to 60 years old. Women were enrolled voluntarily and randomly received 20, 30, or 50 mg Pueraria mirifica in capsules or identical placebo once daily for 24 weeks. Outcome measures were lipid profiles, bone-specific alkaline phosphatase level, endometrial thickness, endometrial histology, breast ultrasonography, complete blood count, liver function test, and renal function test.
Results:
After 24 weeks of treatment, 71 women were evaluated. Of the 71 women, 51 randomly received varying doses of Pueraria mirifica and 20 received placebo. Pueraria mirifica and placebo significantly increased triglyceride levels by 15% from baseline levels (P < 0.05). The Pueraria mirifica group showed a significant decrease in bone-specific alkaline phosphatase levels after 24 weeks of treatment compared with the placebo group; from 0.22 ± 0.18 U/L to 0.13 ± 0.01 U/L in the Pueraria mirifica group and from 0.20 ± 0.10 U/L to 0.20 ± 0.14 U/L in the placebo group. Endometrial thickness did not change after treatment in both groups (P > 0.05). No endometrial proliferation or hyperplasia was reported after 24 weeks of treatment in both groups. There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.
Conclusion:
Pueraria mirifica at a dose of 20, 30, and 50 mg/d for a 24-week period demonstrated an estrogen-like effect on bone turnover rate. Pueraria mirifica did not demonstrate an estrogen-like effect on endometrial thickness and endometrial histology. Mild adverse effects occurred after Pueraria mirifica and placebo treatment.
https://journals.lww.com/menopausejournal/abstract/2008/15030/effects_and_safety_of_pueraria_mirifica_on_lipid.22.aspx
Pueraria mirifica group showed a significant decrease in bone-specific alkaline phosphatase levels after 24 weeks of treatment compared with the placebo group; from 0.22 ± 0.18 U/L to 0.13 ± 0.01 U/L in the Pueraria mirifica group and from 0.20 ± 0.10 U/L to 0.20 ± 0.14 U/L in the placebo group
Given patient’s desire for partial transition, low dose transdermal estradiol 0.05 mg patch and spironolactone 50mg BID started. On above regimen, estradiol was 179 pg/mL and total testosterone suppressed at 72 ng/dL. The patient’s triglycerides remained <150 mg/dL with no further complications.